

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RemeGen Co., Ltd.*

榮昌生物製藥(煙台)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE

This announcement is made by RemeGen Co., Ltd.* 榮昌生物製藥(煙台)股份有限公司 (the “**Company**”) on a voluntary basis.

The board of directors of the Company (the “**Board**”) is pleased to announce today that the results of the Phase III study of telitacept (RC18, brand name: 泰爱®), the Company’s independently developed innovative dual-target fusion protein drug targeting B-cell lymphocyte stimulator/a proliferation inducing ligand (BLyS/APRIL), for the treatment of generalized myasthenia gravis (gMG) were selected as the “latest breakthrough study” for the heavyweight oral presentation at the 2025 American Academy of Neurology Annual Meeting (the “**AAN**”) to be held on April 8, 2025 at San Diego Convention Center, the United States of America. The title of this oral presentation will be “Efficacy and Safety of Telitacept in Patients with Generalized Myasthenia Gravis: Results of a Phase 3 Study”. The 2025 AAN’s 77th Annual Meeting will be held from April 5 to 9, 2025 in San Diego, the United States of America. The AAN Annual Meeting is one of the largest neuroscience events in the world.

Warning under Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the telitacept (RC18, brand name: 泰爱®) (for the treatment of other indications) will ultimately be successfully marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
RemeGen Co., Ltd.*
Mr. Wang Weidong
Chairman and executive director

Yantai, The People’s Republic of China
March 17, 2025

As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin and Mr. Lin Jian as the executive directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive directors, and Mr. Hao Xianjing, Mr. Chen Yunjin and Mr. Huang Guobin as the independent non-executive directors.

* For identification purpose only